INTRODUCTION {#S1}
============

How ubiquitous epigenetic factors and transcription factors cooperate in a time-dependent manner to direct cell fate remains largely unexplored. In embryonic stem cells (ESCs), WDR5 is highly expressed and decreases during differentiation but remains present in somatic cells ([@R2]). Broad WDR5 expression is thought to be related to its "epigenetic house-keeping function": methylation of lysine 4 on histone H3 (H3K4me) via the KMT2 (MLL) histone methyltransferase family. This histone mark is linked to transcription and, thus, WDR5 contributes to regulation of gene expression ([@R7]; [@R36]).

WDR5 interacts with OCT4, CTCF, or lncRNA to facilitate induced pluripotent stem cell reprogramming and maintains ESC identity ([@R2]; [@R54]). *Wdr5* haploin-sufficiency in fetal mesoderm triggers somitogenesis defects and WDR5 overexpression accelerates Wnt-mediated osteoblast differentiation ([@R14]; [@R49]). *WDR5* point mutations are linked to congenital heart defects ([@R56]; [@R60]) and disrupted speech development ([@R11]) in humans. Still, the role of WDR5 in cell fate determination immediately following exit from pluripotency remains enigmatic.

Like WDR5, p53 is enriched in ESCs and decreases during differentiation ([@R30]). p53 is ubiquitous in the mouse embryo up to day 11 ([@R30]; [@R41]; [@R37]). Its abundance and enhanced stability in ESCs suggest roles that may contrast from its function in somatic cells, in which p53 is degraded rapidly by MDM2, and regulates the DNA damage response ([@R17]; [@R39]; [@R13]). Moreover, p53 hyperactivation occurs in several developmental syndromes (e.g., CHARGE and others) that feature neuroectoderm (NE) defects ([@R5]).

Here, we identify a regulatory role for WDR5 on the activity of p53 during key ESC cell fate transitions. Molecularly, we found that WDR5 regulates p53 stability and directly interacts with p53 during ESC specification. Intact *Wdr5* activity or brief *Wdr5* inhibition leads to a distinct chromatin landscape in which WDR5 directly targets NE genes and favors transcription of NE lineage-specifying genes and differentiation of NE organoids. In contrast, prolonged *Wdr5* inhibition causes dysregulated ribosomal protein (RP) gene expression and enhanced p53 stability, which leads to p53 activation. Increased p53 activity promotes mesoderm specification, as well as a global chromatin accessibility landscape that is permissive for mesoderm differentiation. *Wdr5* rescue redirects WDR5 to mesoderm lineage-identity genes, which promotes differentiation toward contractile cardiogenic and hematopoietic mesoderm fates in a p53-dependent manner. This WDR5-p53 cell fate pathway offers a previously unrecognized example of how a broadly expressed epigenetic factor and embryonically abundant protein coordinate ESC lineage specification and differentiation in a time-dependent manner.

RESULTS {#S2}
=======

The WDR5-RbBP5 Interaction Surface Controls *Rx*^+^ NE Differentiation {#S3}
----------------------------------------------------------------------

WDR5 is essential for mouse ESC (mESC) self-renewal and viability ([@R2]). To determine whether WDR5 temporally regulates NE differentiation from ESCs, we used CRISPR-Cas9 and piggyBac transposon-based strategies to create "rescue" complementation ESC lines in which endogenous *mWdr5* is replaced by a Tet-On, doxycycline (Dox)-inducible HA-tagged, human *hWDR5,* allowing temporal control of WDR5 expression. hWDR5 protein is 100% identical to mWDR5 ([@R28]). This approach allows *mWdr5* editing without altering *hWDR5.* We used Rx-GFP ESC lines, which contain GFP reporter knocked in to the endogenous NE-specific *Rax/Rx* promoter; these lines efficiently generate *Rx*^*+*^ NE organoids via serum-free embryoid body (EB)-like aggregates with quick reaggregation (SFEBq) culture ([@R4]; [@R10]). We derived four independently targeted, *hWDR5*^*Dox*^;*mWdr5*^*KO*^ (*WDR5*^*Dox*^;*Wdr5*^*KO*^) Rx-GFP mESC lines ([Figures S1A](#SD1){ref-type="supplementary-material"}--[S1F](#SD1){ref-type="supplementary-material"}). Interestingly, while *Wdr5* transcripts decreased during NE differentiation, *Wdr5* mRNA was expressed in both *Rx*^+^ and *Rx*^−^ EBs ([Figure S1A](#SD1){ref-type="supplementary-material"}). hWDR5 expression did not alter *Rx*^*+*^ NE induction in wild-type (WT) ESCs ([Figures S1B](#SD1){ref-type="supplementary-material"} and [S1C](#SD1){ref-type="supplementary-material"}). In *Wdr5*^KO^ EBs, Dox removal decreased hWDR5 ([Figure S1G](#SD1){ref-type="supplementary-material"}) and global histone marks H3K4Me2/3, but not H3K4Me1 ([Figure S1H](#SD1){ref-type="supplementary-material"}), consistent with the histone-modifying function of WDR5 ([@R52]).

Next, we assessed the role of WDR5 in NE differentiation. Impaired cell proliferation and *Rx*^*+*^ NE differentiation of *Wdr5*^*KO*^ EBs was rescued by Dox-induced WDR5 in a dose-dependent manner ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). To test whether interaction of known WDR5 co-factors ([@R52]), MLL1 and RbBP5, with WDR5 is essential for NE differentiation, we expressed FLAG-tagged WT or mutant WDR5 into *WDR5*^*Dox*^;*Wdr5*^*KO*^ ESCs ([Figure S11](#SD1){ref-type="supplementary-material"}). Surprisingly, *Wdr5*^*KO*^ EBs expressing WDR5-MLL1 mutants (WDR5^F133Y^ or WDR5^I305V^) proliferated and differentiated to *Rx*^*+*^ NE normally ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). *Wdr5*^*KO*^ EBs constitutively expressing WDR5-RbBP5-binding mutants WDR5^N225A^, WDR5^L240K^, WDR5^V268E^, or WDR5^Q289E^ showed reduced NE differentiation ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}) and *Rx* mRNA ([Figure 1E](#F1){ref-type="fig"}). Defective NE differentiation of WDR5-RbBP5-binding mutants, except for WDR5^Q289E^, could not be fully rescued with WT WDR5 induced by Dox at 12 h following NE differentiation (T12h; [Figures 1C](#F1){ref-type="fig"}--[1F](#F1){ref-type="fig"}). We next derived dexamethasone (Dex) and Dox double-inducible *Wdr5*^KO^ ESCs ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}), in order to express WDR5-RbBP5 interaction mutants at similar levels. Dex treatment induced translocation of cytoplasmic WT WDR5 to the nucleus in *Wdr5*^KO^ ESCs, which maintained ESC pluripotency and self-renewal (data not shown). Both Dex-induced nuclear WT-WDR5 and Dox-inducible WT-WDR5 supported NE proliferation in *Wdr5*^KO^ EBs in monolayer and suspension-based NE differentiation culture conditions ([Figures S2C](#SD1){ref-type="supplementary-material"} and [S2D](#SD1){ref-type="supplementary-material"}). However, Dox-induced expression of WDR5-RbBP5-binding mutants, expressed at similar levels ([Figure S2B](#SD1){ref-type="supplementary-material"}) in *Wdr5*^KO^ EBs, showed defective NE differentiation ([Figures 1G](#F1){ref-type="fig"}, [S2C](#SD1){ref-type="supplementary-material"}, and [S2D](#SD1){ref-type="supplementary-material"}). Together, we find specific interaction surfaces of WDR5 and RbBP5 are required for *Rx*^*+*^ NE differentiation.

Timing of WDR5 Expression in ESCs Mediates an NE versus Mesoderm Fate Decision {#S4}
------------------------------------------------------------------------------

To determine whether WDR5 exerts time-dependent effects on lineage-specific ESC differentiation, we rescued *Wdr5*^KO^ EBs with Dox-inducible WDR5 at consecutive 12-h intervals ([Figure 2A](#F2){ref-type="fig"}). Induction of WDR5 from T12--24h after differentiation (hereafter termed "early void," "early rescue," or brief inhibition \[of WDR5\]) maintained EB proliferation and stimulated NE differentiation ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}). However, WDR5 induction at T36--48h after differentiation (hereafter named as "extended void," "late rescue," or prolonged inhibition) maintained *Wdr5*^*KO*^ EB growth but impaired NE formation. Unlike WT or early-void groups, virtually all extended-void EBs spontaneously contracted by days 8--9, suggesting cardiogenic mesoderm (MES) differentiation. Time-course qRT-PCR analysis showed induced cardiomyocyte-lineage transcripts in three independent *WDR5*^*Dox*^;*Wdr5*^*KO*^ ESC lines in extended-void conditions such as *Ncad* ([@R19]), *cTnT, αMHC, βMHC,* and *Myocd* mRNA ([Figures 2B](#F2){ref-type="fig"} and [S3C](#SD1){ref-type="supplementary-material"}--[S3E](#SD1){ref-type="supplementary-material"}). Cardiogenic-lineage-specific proteins such as intracellular N-cadherin, cTnT (CT3), and myosin heavy chain (MF20) were also present ([Figure 2C](#F2){ref-type="fig"}). In contrast, WT and early-void groups showed induction of NE-specific *Rx* mRNA ([Figures 2B](#F2){ref-type="fig"} and [S3D](#SD1){ref-type="supplementary-material"}), Moreover, N-cadherin exhibited NE-specific apical localization in WT or *Wdr5*^KO^ EBs with Dox-inducible WDR5 in early-void groups ([Figure 2C](#F2){ref-type="fig"}) ([@R8]). Time-course western blotting analyses confirmed expression of exogenous WDR5 protein in *Wdr5* knockout (KO) EBs with Dox-inducible early and extended voids ([Figure S3F](#SD1){ref-type="supplementary-material"}). Cardiogenic MES differentiation was both WDR5 time ([Figure 2D](#F2){ref-type="fig"}) and dose dependent ([Figure 2E](#F2){ref-type="fig"}), indicating that MES induction is specific to WDR5 and not simply a "default" pathway for ESC differentiation. Further, generation of cardiogenic MES was genetically driven by *Wdr5* and independent of external cues specific to SFEBq differentiation such as retinoic acid receptor antagonism, or specific lots of matrigel or KO serum replacement ([Figure 2F](#F2){ref-type="fig"}; data not shown). Induction of the MES master transcription factor (TF) *T/Brachyury* in *Wdr5*^KO^ EBs with extended voids ([Figure 2F](#F2){ref-type="fig"}) prompted us to examine whether other MES lineages may form in these conditions. When *Wdr5*^KO^ EBs with extended voids were seeded into methylcellulose-based differentiation medium at day 6 or 9 for secondary hematopoietic differentiation ([Figure 2G](#F2){ref-type="fig"}, upper panel), colony-forming units of granulocyte-macrophage progenitor cells (CFU-GM, CFU-G, and CFU-M) arose, which were not observed in *Wdr5*^KO^ EBs with early voids ([Figure 2G](#F2){ref-type="fig"}, lower panel; [Figures S3G](#SD1){ref-type="supplementary-material"} and [S3H](#SD1){ref-type="supplementary-material"}). These data demonstrate that an extended void in *Wdr5*^KO^ EBs stimulates ESCs toward cardiogenic and hematopoietic MES fates. This time-dependent ESC fate transition to MES occurs in SFEBq conditions, which does not contain the exogenous cytokines or fetal calf serum usually required for ESC-derived MES differentiation ([@R51]; [@R9], [@R10]). These findings demonstrate that the length of time of *Wdr5* inhibition, followed by subsequent WDR5 rescue, determines whether ESCs differentiate toward NE versus MES-specific lineages. Since continuous and early voids (T12h) stimulate NE differentiation, and an extended void (T36--48h) promotes cardiogenic or hematopoietic MES formation, we further conclude that EB day 2 (T48h) defines a crucial period of lineage specification during which differentiating ESCs make an NE versus MES fate decision.

The WDR5-RbBP5 Interaction Surface Regulates Mesoderm-Related Transcription {#S5}
---------------------------------------------------------------------------

We next asked whether the WDR5-RbBP5 interaction surface regulates cardiogenic MES induction. *Wdr5*^KO^ EBs expressing constitutive WDR5^N225A,\ L240K\ or\ V268E^ mutants showed \~50û300-fold induction of *cTnT* mRNA ([Figure 2H](#F2){ref-type="fig"}, left panel). This pro-cardiogenic MES induction effect was inhibited by concomitant rescue of WT WDR5 at T12h ([Figure 2H](#F2){ref-type="fig"}, left panel). However, WDR5^Q289E^ had similar capacity as WT WDR5 to repress *cTnT* mRNA upregulation in *Wdr5*^KO^ EBs ([Figure 2H](#F2){ref-type="fig"}, right panel). Thus, while the WDR5-RbBP5 interaction promotes NE fates ([Figure 1C](#F1){ref-type="fig"}), it only partially restrains transcription of cardiogenic MES-related genes.

WDR5 Regulates Overlapping and Distinct Direct Target Genes in Divergent Cell Lineages {#S6}
--------------------------------------------------------------------------------------

To identify molecular targets for WDR5 in *Rx*^*+*^ NE and cardiogenic MES lineages, we performed RNA sequencing (RNA-seq) from EB day 6 RNA isolated from four groups: WT, *Wdr5*^*KO*^*, Wdr5*^*KO*^ with early (T12h^Rescue^), or extended (T48h^Rescue^) void. The majority of differentially expressed transcripts arose, and overlapped (75%--80%; [Figure 3A](#F3){ref-type="fig"}), in WT versus T48h^Rescue^ (2,758), and T12h^Rescue^ versus T48^Rescue^ (2,937) groups ([Figure S4A](#SD1){ref-type="supplementary-material"}), compared to those of WT versus T12h^Rescue^ groups (593; [Figure S4A](#SD1){ref-type="supplementary-material"}). These data indicate that transcriptomes of WT and T12h^Rescue^ groups were comparable and harbored RNA profiles distinct from T48h^Rescue^ and *Wdr5*^KO^ groups ([Figure S4B](#SD1){ref-type="supplementary-material"}). Gene Ontology (GO) themes in the T12h^Rescue^ group included NE development, while those of the T48h^Rescue^ group emphasized MES specification ([Figure 3B](#F3){ref-type="fig"}). RNA-seq analysis indicated that trophectoderm markers (*Cdx2* and *Gata3*) and endoderm markers (*Gata4* and *Gata6*) were upregulated in T48h^Rescue^ group (data not shown). Time-course qRT-PCR analysis showed that *Cdx2* and *Gata3* mRNA were transiently upregulated in T36--48h^Rescue^ groups during differentiation, to a greater degree than in the WT and T12h^Rescue^ groups ([Figure 3C](#F3){ref-type="fig"}; data not shown), consistent with a previous report ([@R2]). However, the lack of concomitant endoderm-specific *Foxa2* upregulation suggested that *Gata4* upregulation suggests formation of lateral mesoderm rather than endoderm in T36--48h^Rescue^ groups ([Figure 3C](#F3){ref-type="fig"}) ([@R38]).

To define direct target genes of WDR5 in NE and MES lineages, we performed HA-WDR5 chromatin immunoprecipitation sequencing (ChIP-seq) in *Wdr5*^KO^ EBs with T12h^Rescue^ and T48h^Rescue^ at EB day 6. We found that in both groups, WDR5 bound to intergenic, intron, and promoter regions ([Figure S4C](#SD1){ref-type="supplementary-material"}). Using peak centers of HA-WDR5-bound targets in the T12h^Rescue^ or T48h^Rescue^ group ([Figure 3D](#F3){ref-type="fig"}) as references, we found that WDR5 bound both overlapping and distinct targets. In both NE organoids and MES-enriched EBs, we identified distinct *de novo* and known WDR5 target DNA motifs, including consensus sites shared with c-MYC, consistent with a previous report ([Figure S4D](#SD1){ref-type="supplementary-material"}) ([@R46]). Integration of ChIP-seq with RNA-seq datasets revealed WDR5-bound targets that were associated with \>2-fold differential gene expression ([Figure S4E](#SD1){ref-type="supplementary-material"}). Such WDR5 direct target genes in the T12h^Rescue^ group (123 genes: 76 and 47 genes down- and upregulated, respectively) included NE-related genes such as *Sox2, Nestin, Sfrp2,* and others ([Figures 3E](#F3){ref-type="fig"} and [S4E](#SD1){ref-type="supplementary-material"}). In the T48h^Rescue^ group (45 genes: 25 and 20 genes down- and upregulated, respectively), these included MES-associated genes such as *Pabpc4l, Nr3c1, Egln3,* and others ([Figures 3E](#F3){ref-type="fig"} and [S4E](#SD1){ref-type="supplementary-material"}). 22 direct WDR5 target genes (10 and 12 genes down- and upregulated, respectively) overlapped in both the NE and MES lineages, including *Efcab12, Esrrb, Brn2,* and 8 RP genes such as *Rpl5* and *Rpl37* ([Figure S4E](#SD1){ref-type="supplementary-material"}). These data show that WDR5 targets both overlapping and distinct genes in NE organoids and MES-enriched EBs.

WDR5 Regulates Target Gene Expression with Dynamic Chromatin Accessibility during ESC Lineage Specification {#S7}
-----------------------------------------------------------------------------------------------------------

WDR5 is a core member of the MLL chromatin-modifying complex and is essential for H3K4me3 formation ([Figure S1H](#SD1){ref-type="supplementary-material"}) ([@R7]; [@R36]). Having established that WDR5 regulates differentiation of *Rx*^*+*^ NE and cardiogenic MES lineages at EB day 6, we sought to understand chromatin-related events that precede the formation of these distinct lineages, in WT EBs and immediately before T48h^Rescue^ in *Wdr5*^*KO*^ EBs, during the lineage specification period (EB day 2). RNA-seq analyses at EB day 2 revealed that \~60% of differentially expressed genes were downregulated in *Wdr5*^*KO*^ EBs ([Figure 4A](#F4){ref-type="fig"}). We used CUT&RUN (cleavage under targets and release using nuclease sequencing) to define the genomic targets of WDR5 and H3K4me3 in WT and *Wdr5*^*KO*^ EBs at day 2 ([Figure 4B](#F4){ref-type="fig"}) ([@R32]). H3K4me3 at WT WDR5-bound chromatin targets were reduced in *Wdr5*^*KO*^ EBs ([Figure 4C](#F4){ref-type="fig"}). Genome-wide integration of WDR5-bound peaks from CUT&RUN with transcripts from RNA-seq data elucidated direct WDR5 target genes during EB day 2 lineage specification ([Figure 4D](#F4){ref-type="fig"}). In *Wdr5*^*KO*^ EBs, we detected 33 WDR5 direct target genes. Of 33 genes, 20 were downregulated including *Rpl29* and *E2f3,* which are genes essential for NE proliferation or differentiation while 13 genes were upregulated including *Nodal,* which is required for MES specification. Interestingly, differentially expressed transcripts of WDR5 direct target genes in day 2 WT and *Wdr5*^*KO*^ EBs overlapped with those of day 6 WT and *Wdr5*^*KO*^ EBs ([Figure S5A](#SD1){ref-type="supplementary-material"}).

As *Wdr5* deletion led to both down- and upregulated direct target genes, we posited that WDR5-mediated canonical (transcriptional activation) and non-canonical H3K4me3 (transcriptional repression) chromatin mechanisms contribute to WDR5-mediated target gene regulation ([@R57]). To this end, we performed ATAC-seq to determine whether WDR5 regulates "open and closed" chromatin accessibility regions at NE and MES lineage-identity genes. Genome-wide analyses revealed that genes with loss of H3K4me3 mark correlated, to some extent, with reduced chromatin accessibility in day 2 *Wdr5*^KO^ EBs ([Figure 4F](#F4){ref-type="fig"}). We observed increased ("open") chromatin accessibility at the NE-specific gene *Rx* transcription start site (TSS) region as early as EB day 4 in WT and T12h^Rescue^ groups, indicating proper NE specification ([Figure 4E](#F4){ref-type="fig"}). In contrast, chromatin accessibility at the *Rx* TSS region remained inaccessible ("closed") during the day 2--6 differentiation period in *Wdr5*^KO^ EBs with the T48h^Rescue^ group. For the MES-specific gene *cTnT/Tnnt2,* opening peaks were observed at its TSS in *Wdr5*^KO^ EBs with T48h^Rescue^ until EB day 6 differentiation, but not in WT and T12h^Rescue^ groups ([Figure 4E](#F4){ref-type="fig"}).

We next sought to gain insights into WDR5-dependent, chromatin accessibility during lineage specification (EB day 2). Decreased chromatin accessibility in *Wdr5*^KO^ EBs at day 2 was associated with NE-pathways ([Figures 4G](#F4){ref-type="fig"} and [S5B](#SD1){ref-type="supplementary-material"}) and motif analysis of those closing peaks correlated with the NE master regulator SOX1 ([Figure S5C](#SD1){ref-type="supplementary-material"}). Increased chromatin accessibility in *Wdr5*^KO^ EBs at day 2 was associated with Hippo, Wnt, and p53-signaling pathways ([Figures 4G](#F4){ref-type="fig"} and [S5B](#SD1){ref-type="supplementary-material"}) and motif analysis of those open peaks correlated with transcription factor NF-YB and YY1 ([Figure S5C](#SD1){ref-type="supplementary-material"}). Indeed, activation of p53 and Wnt signaling pathways, and the transcription factor YY1, have been previously reported to promote MES differentiation ([@R50]; [@R15]). Hyperactivation of the Hippo pathway and overexpression of YAP impairs neural differentiation in mESCs ([@R29]), which is consistent with defective NE differentiation in *Wdr5*^*KO*^ EBs. Collectively, these data show that prolonged *Wdr5* inactivation triggers alterations in chromatin accessibility and target gene expression that are permissive for MES differentiation and repressive for NE induction.

*p53* Signaling Contributes to the NE versus Cardiogenic MES Cell Fate Decision {#S8}
-------------------------------------------------------------------------------

p53 signaling emerged as a common theme in GO analyses of opening peaks in ATAC-seq ([Figure 4G](#F4){ref-type="fig"}) and of RNA-seq in *Wdr5*^KO^ EBs at days 2 and 6, respectively ([Figures 4G](#F4){ref-type="fig"} and [S5D](#SD1){ref-type="supplementary-material"}). Indeed, the *p53* direct target gene *Cdkn1a* mRNA in *Wdr5*^KO^ EBs was upregulated at days 2 and 3 ([Figure 6C](#F6){ref-type="fig"}). To test whether p53 activation regulates *Wdr5-*mediated NE and MES fate choice, we edited *p53* via CRISPR-Cas9 to derive *WDR5*^*Dox*^;*Wdr5*^KO^ Rx-GFP ESC lines ([Figures S6A](#SD1){ref-type="supplementary-material"} and [S6B](#SD1){ref-type="supplementary-material"}). *p53* and *Wdr5* double-knockout (DKO) EBs showed reduced expression of p53 direct target genes *Cdkn1a* and *Bax* ([Figures 6C](#F6){ref-type="fig"} and [S6C](#SD1){ref-type="supplementary-material"}). While *p53* deletion rescued cell proliferation defects in *Wdr5*^*KO*^ EBs at EB day 4 ([Figure 5A](#F5){ref-type="fig"}), neither *Rx*^*+*^ NE nor cardiogenic MES arose from DKO EBs ([Figure 5B](#F5){ref-type="fig"}; data not shown), suggesting that p53 harbors proliferation-independent effects on cell fate.

Next, we added Dox (WDR5 rescue) to DKO EBs at T12h or T36--48h, which allowed us to determine whether *p53* regulates WDR5-driven NE versus MES fate choice. Similar to *Wdr5*^KO^ EBs, early void (Dox, T12h) in DKO EBs stimulated Rx^+^ NE differentiation ([Figures 5B](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}; [Videos S1](#SD2){ref-type="supplementary-material"}, [S3](#SD4){ref-type="supplementary-material"}, and [S5](#SD6){ref-type="supplementary-material"}). Rx^+^ NE induction was WDR5 dose dependent ([Figure 5C](#F5){ref-type="fig"}). Notably, unlike *Wdr5*^KO^ EBs with an extended void, which induces cardiogenic MES differentiation ([Figure 5E](#F5){ref-type="fig"}; [Video S4](#SD5){ref-type="supplementary-material"}), DKO EBs with extended voids (Dox, T36--48h) did not form cardiogenic MES ([Figure 5E](#F5){ref-type="fig"}; [Video S6](#SD7){ref-type="supplementary-material"}). Instead, *Rx*^*+*^ NE differentiation occurred ([Figures 5B](#F5){ref-type="fig"}, [5D](#F5){ref-type="fig"}, [5E](#F5){ref-type="fig"}, and [S6D](#SD1){ref-type="supplementary-material"}). Corroborating these findings, EB day 6 ATAC-seq analyses revealed that NE-specific, open, unique peaks (chromatin accessible regions) in WT EBs that had closed (reduced chromatin accessibility) in *Wdr5*^KO^ EBs with T48h^Rescue^ were restored to an open state in DKO EBs ([Figure 5F](#F5){ref-type="fig"}). Similarly, unique, opening peaks associated with MES specification in *Wdr5*^KO^ EBs with T48h^Rescue^ had closed in DKO EBs ([Figure 5F](#F5){ref-type="fig"}). Thus, p53 controls the cardiogenic MES versus *Rx*^*+*^ NE fate choice in Wdr5^KO^ EBs.

WDR5 Regulates p53-Dependent Chromatin Accessibility, Histone Methylation, and Transcription during ESC Lineage Specification {#S9}
-----------------------------------------------------------------------------------------------------------------------------

Next, we wondered whether WDR5 and p53 regulate common target genes during ESC lineage specification. We compared EB day 2 ATAC-seq chromatin accessibility profiles of control (*Wdr5*^KO^ with T12h^Rescue^), *Wdr5*^*KO*^, and DKO EBs. *p53* deletion reversed closed peaks observed in day 2 *Wdr5*^KO^ EBs (increased chromatin accessibility at regions of previously decreased accessibility) when compared to control ([Figure 6A](#F6){ref-type="fig"}). Compared to the T12h^Rescue^ group, opening peaks in *Wdr5*^*KO*^ EBs modestly reverted ("closed") upon *p53* deletion ([Figure 6A](#F6){ref-type="fig"}).

To determine whether the above changes in chromatin accessibility lead to transcriptional changes, RNA-seq was performed on day 2 WT, *Wdr5*^KO^, or DKO EBs from two independent ESC lines. Among 736 downregulated genes in *Wdr5*^KO^ EBs, 63% (464) of the genes were rescued by *p53* deletion in DKO EBs ([Figures S6E](#SD1){ref-type="supplementary-material"}, [6B](#SD1){ref-type="supplementary-material"}, and [6C](#SD1){ref-type="supplementary-material"}). Among these genes, *Bcl2l14* is a direct p53 target gene and downregulation or mutation of genes including *Fras1, Thy1, Meis1,* and *Vax2OS* has been reported in NE defects including eye development, which is consistent with phenotypes observed later in day 6 *Wdr5*^KO^ EBs ([Figure 1B](#F1){ref-type="fig"}). Among 440 upregulated genes in *Wdr5*^KO^ EBs, 60% (262) of the genes were rescued by *p53* deletion in DKO EBs ([Figures 6B](#F6){ref-type="fig"} and [S6E](#SD1){ref-type="supplementary-material"}). Among these genes, *Cdkn1a* is a known p53 target gene ([Figure 6C](#F6){ref-type="fig"}) and *Wnt3* is a p53 direct target that in ESCs promotes MES differentiation ([@R50]). Genes essential for MES specification such as *Mesp2, Lefty1, Nodal,* or *Pitx2* were upregulated in *Wdr5*^KO^ EBs but were repressed by *p53* deletion in DKO EBs. Interestingly, reduced H3K4me3 at WT WDR5-bound peaks in *Wdr5*^KO^ EBs was partially rescued by *p53* deletion ([Figure 6D](#F6){ref-type="fig"}). Thus, WDR5 regulates p53-dependent chromatin accessibility, H3K4me3, and transcription during ESC specification.

WDR5 Regulates p53 Protein Stability and Directly Interacts with p53 during ESC Specification {#S10}
---------------------------------------------------------------------------------------------

Next, we sought to explore the mechanism(s) by which WDR5 regulates p53. We found that *Wdr5* extended void did not alter *p53* transcripts ([Figure 7A](#F7){ref-type="fig"}) ([@R45]; [@R53]). We noticed that ChIP-seq peaks representing WDR5 bound to RP genes were overrepresented ([Figures S4E](#SD1){ref-type="supplementary-material"} and [S7A](#SD1){ref-type="supplementary-material"}; data not shown). Downregulation of a subset of RP genes was confirmed by RNA-seq ([Figure S7B](#SD1){ref-type="supplementary-material"}). It is known that reduced RP gene transcription triggers defects in ribosome biogenesis, which upregulates p53 activity via MDM2 inhibition (RP-MDM2-p53 pathway) ([@R31]). *Wdr5* deletion (EB day 2) and an extended void (EB day 6) led to downregulation of WDR5-bound RP genes including *Rpl5, Rpl24,* and *Rpl29* ([Figures 7B](#F7){ref-type="fig"}, [7C](#F7){ref-type="fig"}, and [S7A](#SD1){ref-type="supplementary-material"}). These data suggest that p53 activation due to *Wdr5* deletion can be, in part, due to perturbation of WDR5-bound, RP target genes.

While p53 transcripts during lineage specification of WT and *Wdr5*^KO^ EBs were comparable ([Figure 7A](#F7){ref-type="fig"}), *Wdr5*^KO^ EBs harbored elevated p53 protein levels ([Figure 7D](#F7){ref-type="fig"}). We treated WT and *Wdr5*^KO^ EBs with the protein translation inhibitor cycloheximide (CHX), which showed that p53 stability was enhanced in *Wdr5*^KO^ EBs ([Figure 7D](#F7){ref-type="fig"}). How does WDR5 regulate p53 stability? Post-translational modifications (PTMs) such as serine (S), phosphorylation (p), and lysine (K) acetylation (Ac) stabilize p53 ([@R16]). Indeed, we found that *Wdr5* deletion in *Wdr5*^KO^ EBs increased p53 PTMs at p-p53^S15^, p-p53^S392^, Ac-p53^K305^, and Ac-p53^K379^; WDR5 rescue reduced these PTMs ([Figure S7C](#SD1){ref-type="supplementary-material"}). Moreover, using immunofluorescence, we observed that prolonged deletion of *Wdr5* led to increased nuclear p53 ([Figures S7D](#SD1){ref-type="supplementary-material"} and [S7E](#SD1){ref-type="supplementary-material"}). Together, *Wdr5* deletion triggers PTMs that stabilize p53 and increase nuclear p53 activity, as evidenced by enhanced p53 stability and increased transcription of *p53* direct target genes ([Figure 6C](#F6){ref-type="fig"}).

Finally, by immunoprecipitation, we found that endogenous WDR5 and p53 physically interact during ESC specification ([Figure 7E](#F7){ref-type="fig"}). We performed p53 CUT&RUN at EB day 2 and integrated the data with that of WDR5 CUT&RUN at EB day 2 ([Figure 7F](#F7){ref-type="fig"}). We found co-recruitment of WDR5 and p53 to *Rap2b, Irf2bp2,* and *Sox2* ([Figure 7G](#F7){ref-type="fig"}). qRT-PCR confirmed that these direct, joint target genes displayed differential mRNA expression in WT and *Wdr5*^KO^ EBs, and that *p53* deletion partially rescued defective transcription of these genes in *Wdr5*^KO^ EBs ([Figures 7H](#F7){ref-type="fig"} and [S7F](#SD1){ref-type="supplementary-material"}). Notably, *Rap2b* and *Irf2bp2* are known direct targets of p53; these genes regulate cell proliferation ([@R58]; [@R25]). p53 CUT&RUN of WT EBs at day 2 revealed that p53-bound motifs at target loci are shared with motifs bound by pro-MES TF NKX2.5 (data not shown). Thus, WDR5 directly interacts with p53 and regulates p53 activity via direct and indirect PTMs during ESC specification.

DISCUSSION {#S11}
==========

Transcription factors expressed at a particular time and location, and at proper magnitude during development, have traditionally been the focus of studies of cell fate determination. In contrast, our study, using an ESC-to-organoid platform, unmasks time-dependent roles for the ubiquitous epigenetic protein and TF, WDR5 and p53, respectively, to control ESC fate choice.

Several WDR5-driven mechanisms regulate ESC differentiation. First, specific interaction sites that mediate WDR5-RbBP5 binding are required for NE differentiation. Second, WDR5 regulates p53 stability. WDR5 targets and transcriptionally activates a subset of RP genes. *Wdr5* deletion leads to reduced transcription of these RP genes, triggering p53 activation via RP-MDM2-p53 pathway and to PTMs that increase p53 stability. Indeed, while this work was under review, a report independently confirmed our findings, which showed that RP genes are direct WDR5 targets and that WDR5 inhibition triggers p53 upregulation via the RP-MDM2-p53 pathway in leukemia cells ([@R1]). Third, during lineage specification, *Wdr5* deletion derepresses the WDR5 direct target gene and MES TF *Nodal*; induced p53 activation from *Wdr5* loss promotes MES lineage specification. p53 targets motifs on loci shared with another MES TF NKX2.5 (data not shown). Thus, WDR5 suppresses cardiogenic MES and promotes NE-specific chromatin accessibility, transcription, and cell fate in a p53-dependent manner. Indeed, impaired H3K4me3 deposition, chromatin accessibility, transcription, and NE specification in *Wdr5*^KO^ EBs are partially rescued when *p53* is concurrently deleted. Finally, WDR5 directly interacts with p53 and both are recruited to target genes related to NE fate (*Sox2*) and cell proliferation (*Rap2b* and *Irf2bp2*).

Given that RbBP5, MYC, or KANSL2 bind to the same WDR5 interaction surface in mutually exclusive manner, a central role for this binding surface on WDR5 on the regulation of NE fate is supported from RbBP5 and MYC loss-of-function assays from our study and others ([@R46]). *RbBP5* depletion in ESCs leads to NE differentiation defects and deletion of *c/n-Myc* inhibits NE fates from mESCs ([@R20]; [@R44]). Since we observed enrichment of MYC-associated DNA motifs at WDR5 direct targets in NE-lineage cells at EB day 6, the interplay of WDR5, RbBP5, and MYC on chromatin to regulate NE lineage-identity genes warrants further study.

p53 family members have been shown to regulate NE versus MES cell fate choice during development. In *Xenopus,* p53 promotes MES via an interaction with XFDL156, which represses ectoderm formation ([@R40]). In mESCs, p53/p63/p73 contribute to MES differentiation by integration of WNT-TCF and Nodal-SMAD signaling ([@R50]). Indeed, we show that during prolonged *Wdr5* inhibition, *p53* deletion partially rescues Rx^+^ NE fate and inhibits cardiogenic MES differentiation. In the context of WDR5-dependent regulation, p63 and p73 do not appear to share redundant functions with p53, as *p53* deletion alone is sufficient to stimulate NE and repress MES. Interestingly, p53-associated human syndromes and analogous mouse models feature p53 hyperactivation and NE defects ([@R5]; [@R6]; [@R48]). Importantly, many of the p53-dependent, embryonic NE defects can be partially rescued by *p53* deletion, similar to our work ([@R6]; [@R48]). Still, whether our ESC-based study on the WDR5-p53 cell fate pathway relates to altered developmental events *in vivo* remains unknown.

Several pieces of evidence suggest that an instructive mechanism contributes to the WDR5-p53 cell fate pathway during lineage specification. First, *Wdr5* deletion during a narrow time window (36--48 h after ESC exit from pluripotency) stimulates cardiogenic MES induction, highlighting that a short, 12-h "pulse" of *Wdr5* inhibition initiates MES differentiation. Second, cell proliferation rates did not significantly differ in WT WDR5, *Wdr5*^KO^, or DKO EBs that undergo WDR5 rescue at 36--48 h, and which differentiate to *Rx*^*+*^ NE, cardiogenic MES, or *Rx*^*+*^ NE, respectively. Third, despite rescue of impaired cell proliferation in *Wdr5*^KO^ EBs expressing mutant WDR5^L240K^, ^N225A^, ^V268E^ by WT WDR5, the cardiogenic MES fate is maintained. Fourth, prolonged *Wdr5* inhibition rapidly triggers upregulation of a subset of genes permissive for MES induction. Notably, *Wnt3* is a key p53 direct target gene that promotes MES fate specification from ESCs ([@R50]). Further, we found that WDR5 directly binds the MES master regulator *Nodal,* and that *Nodal* is rapidly derepressed within 36--48 h of *Wdr5* loss during ESC specification. These findings further support an instructive role for WDR5-mediated cardiogenic MES induction ([@R24]).

Here, we define a physical interaction between WDR5 and p53 and find that they jointly bind and regulate common target genes related to cell proliferation (*Rap2b* and *Irf2bp2*) and NE fate (*Sox2*). Whether co-recruitment of WDR5 and p53 "draws" these directly interacting proteins away from other known canonical or non-canonical partners with which WDR5 and p53 interact individually, allowing for transcription of NE genes and suppression of non-NE genes, is a concept that ought to be explored in future studies. Further, it will be important to determine the function of WDR5-p53 protein-protein interaction in p53-associated human syndromes that feature congenital NE defects ([@R5]; [@R48]; [@R6]). Finally, our work informs future translational studies that investigate potential off-target/teratogenic effects of WDR5 inhibitors used for WT and mutant p53-associated cancers, a field that has attracted a \$1 billion investment by industry ([@R3]).

STAR★METHODS {#S12}
============

Detailed methods are provided in the online version of this paper and include the following:

LEAD CONTACT AND MATERIALS AVAILABILITY {#S13}
---------------------------------------

Please direct any requests for further information or regents generated in current manuscript to the lead contact, Dr. Rajesh C. Rao, MD (<rajeshr@umich.edu>). All plasmids and ESC cell lines generated are shared for research and educational purposes under Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S14}
--------------------------------------

### Cell Lines {#S15}

Rx:GFP K/I EB5 mouse ESCs, a subline of mouse embryonic stem cell line, EB5 (129/Ola), in which GFP gene is knocked-in under Rax gene promoter, was ordered from RIKEN Cell Bank (Ibaraki, Japan) ([@R51]). Rx:GFP ESCs were maintained in leukemia inhibitory factor (LIF, ESG1107, Millipore) containing ES media \[GMEM supplemented with 2.5 glutamine (GIBCO), 10% knockout serum replacement, KSR (GIBCO), 1% ES qualified fetal calf serum (FCS), 1 mM sodium pyruvate (Sigma), 0.1 mM non-essential amino acid (Sigma) and 0.1 mM of 2-mercaptoethnal (Sigma)\].

METHOD DETAILS {#S16}
--------------

### ESC Maintenance and Induced Differentiation {#S17}

Rx:GFP ESCs were routinely maintained at 37°C, 5% CO2 in ESC media in the presence of 2,000 IU/ml LIF. Induced differentiation to *Rax* (+) neuroectoderm via 3D (serum-free culture of embryoid-body-like aggregate with quick reaggregation, SFEBq) organoid methods was following a protocol as described previously. Briefly, 5,000 cells were re-suspended in 100 μl of GMEM based differentiation media supplemented with 5% KSR, 1 mM sodium pyruvate, 0.1 mM non-essential amino acid and 0.1 mM of 2-mercaptoethnal and 0.1 μM of retinoic acid receptor antagonist AGN 193109 Sodium Salt (AGN, Santa Cruz) and seeded on each well of 96U ultralow attachment plate (ThermoFisher Scientific) on day 0. On day 1, 50 μl of 2% Matrigel solution (v/v, Corning) was added to embryonic body (EB) suspension. NE differentiation was sustained in 96U plate for 6 to 9 days and differentiation efficiency was monitored by GFP via fluorescent microscopy (OLYPUS IX73) and flow cytometry (BD LSR II). For differentiation of ESCs using SFEBq method without matrigel and AGN, 5,000 cells were re-suspended in 150 μl of GMEM based differentiation media with 10% KSR as described elsewhere ([@R21]). For secondary hematopoietic cell differentiation, day 6 or 9 SFEBq organoids were re-suspended and trypsinized to single cell suspension. 1×10^5^ cells were seeded to methylcellulose based semisolid media M3234 (Stem Cell Technologies) in the presence of IL-3 (10ng/ml), SCF (10ng/ml) and GM-CSF (10ng/ml). After 9 days of differentiation, resultant colony forming units (CFU) were counted under microscope (OLYPUS IX73). For NE differentiation under adherent monolayer condition, we followed a protocol as described elsewhere ([@R55]).

### Plasmids and ESC Transfection {#S18}

Plasmids including pPBCAG-rtTM2-IN, transposase and Doxcycline (Dox) inducible PiggyBac pPBhCMV1cHApA were kindly provided by Dr. Hitoshi Niwa (Kumamoto University, Japan). WT or mutant forms of WDR5 (F133Y, N225A, L240K, V268E, Q289E and I305V) with Flag or HA tags were subcloned into to Dox inducible pPBhCMV1cHApA plasmid, all-in-one Dox inducible Piggybac TREG/Tet3G (subcloning from Addgene \#97421 plasmid by removing dCas9 and APEX2 cassettes), or non-inducible PiggyBac plasmid (Addgene, \#48754). For Dexamethasone inducible WT-WDR5 plasmid, glucocorticoid receptor ligand binding domain (GRBD) was amplified using PCR from pPyCAG-cGR-IP plasmid (catalog \#RDB10440, RIKEN) and Flag-WDR5 and GRBD inframe infusion DNAs were subcloned to non-inducible Piggybac plasmid. For mESC transfection, 20 μg endotoxins free plasmid DNA was electroporated to 5×10^6^ ESCs using mouse ES cell nucleofector® kit (Lonza). Antibiotics resistance ESC colonies were selected for 5 days and pooled or single cell derived clones were picked for further characterization. To generate CRISPR-Cas9 mediated *Wdr5* knockout (KO) plasmid, *Wdr5* guide RNA sequence (TGTGAAGTTCAGCCCCAATG) was sub-cloned into pSpCas9(BB)-2A-Puro (PX459) V2.0 plasmid (Addgene, \#62988). To generate *Wdr5* KO ESC clones harboring with Dox inducible exogenous human WT WDR5 rescue platform (WDR5^Dox^;Wdr5^KO^) or Dex inducible exogenous human WT WDR5 rescue platform (*WDR5*^*Dex*^; *Wdr5*^KO^*),* Dox or Dex inducible WDR5 pooled ESC population were subjected to 2^nd^ round of transfection with *Wdr5* KO plasmid and selected with puromycin (2 μg/ml) in the presence of Dox (2 μg/ml) or Dex (20 μM). Single cell derived ES clones were picked up, expanded, and maintained in presence of Dox or Dex. Sanger sequencing was used to determine DNA editing at expected sites with homozygous Indel mutations with frameshift will be selected and confirmed with western blotting to use as *Wdr5* KO ESC clones. To generate CRISPR-Cas9 mediated *p53* KO plasmids, two independent *p53* guide RNA sequences AAAATGTCTCCTGGCTCAGA or ATAAGCCTGAAAATGTCTCC were sub-cloned into pSpCas9(BB)-2A-Hygro (PX459) V2.0 plasmid. Two independent WDR5^Dox^;*Wdr5*^KO^ ESC lines were transfected with p53 KO plasmids and selected with 200 ug/ml hygromycin in the absence of Dox (2 ug/ml). Single cell clones were picked up and *Wdr5* plus *p53* double knockout (DKO) ESCs were confirmed with DNA Sanger sequencing for homozygous frameshift mutation and western blotting.

### RNA Isolation, Reverse Transcription, and Quantitative Real-Time PCR (RT-qPCR) {#S19}

Trizol reagent (ThermoFisher Scientific) and RNeasy mini kit (QIAGEN) were utilized for RNA isolation from ESCs or EBs. 1.0 μg total RNA was reversely transcribed to cDNA using high-capacity RNA-to-cDNA kit (ThermoFisher Scientific). RT-qPCR was performed using iQ SYBR green supermix (Bio-Rad). Gapdh, β-actin was used as internal control for normalization. Primer sequences for real-time PCR were available upon request. Data were automatically analyzed using Bio-Rad CFX manager software using ΔΔCt method.

### Whole-Cell Lysate Preparation, Histone Extraction, Western Blotting, and Immunoprecipitation {#S20}

ESCs or EBs were lysed with RIPA buffer (Pierce) in the presence of EDTA free protease inhibitor cocktail (Sigma). Histone extraction on EBs was performed using a histone extraction kit (Abcam) as described previously ([@R22]). Protein concentration was determined using Pierce BCA protein assay kit (ThermoFisher Scientific). 1.0 μg of histone extracts, or 10 μg of whole cell lysate was resolved on 4%--20% precast gel (Bio-Rad) was transferred to 0.45 μm PVDF membrane (Millipore). For immunoprecipitation, day 2 WT and *Wdr5*^KO^ EBs were harvested and lysed in RIPA buffer with EDTA free protease inhibitor cocktail (Sigma). 1 mg sonicated cell lysates were subjected to immunoprecipitation using WDR5 antibody (Bethyl). The following primary antibodies were used for probing: anti-HA (1:10,000, Abcam, ab9110), anti-WDR5 (1:5000, R&D), anti-WDR5 (1:5,000, Bethyl), anti-Flag (1:2,000, Sigma), anti-H3 (1:10,000, Abcam), anti-H3K4Me1 (1:5,000, Millipore), anti-H3K4Me2 (1:10,000, Millipore), anti-H3K4Me3 (1:10,000, Abcam), anti-P53 (1:5,000, Cell Signaling), anti-Tubulin (1:10,000, Cell signaling), anti-β-Actin (1:10,000, Cell signaling), anti-Phospho-p53 (Ser15) Antibody (1:5,000, Cell Signaling), anti-Phospho-p53 (Ser392) Antibody (1:5,000, Abcam), anti-Acetyl-p53 (K305) Antibody (1:5,000, Abcam), anti-Actyl-p53 (K379) Antibody (1:5,000, Cell Signaling).

### Immunohistochemistry, Cytospin, and Immunofluorescence Staining {#S21}

Day 9 EBs were harvested and fixed with 4% paraformaldehyde at 4°C overnight. EBs were sent to ULAM (Unit for laboratory animal medicine) at University of Michigan for paraffin processing, embedding, and sectioning. Antigen unmasking on slides was using citric acid methods as prescribed previously ([@R12]). Immunostaining was performed by combining of VectaStain ABC-HRP kit (Vector laboratories) and TSA Kit \#24, with HRP-Streptavidin and Alexa Fluor 568 Tyramide (ThermoFisher Scientific). The primary antibodies were used for staining: anti-N-cadherin (mouse/monoclonal/1:2000, BD), anti- cardiac troponin T (CT3 clone, mouse/monoclonal/1:100, Developmental Studies Hybridoma Bank) and anti-myosin heavy chain antibody (MF20 clone, mouse/monoclonal/1:100, Developmental Studies Hybridoma Bank). For cytospin, Day 2 WT and *Wdr5*^KO^ EBs were harvested and trypsinized to single cell suspension. Cells were attached to EZ cytofunnels (ThermoFisher) slides using Cytospin 3 (Shandon). Cells were fixed with 100% methanol and immunostaining was performed using p53 antibody (NCL-L-P53-CM5P, Leica biosystems) at 1:100 dilution. Counter nuclear staining was performed with DAPI (Molecular Probes). Control sections were incubated without primary antibodies. 4 representative pictures from different field were recorded under fluorescence microscope (Olympus DP73).

### Flow Cytometry {#S22}

2 to 4 EBs (organoids) were combined and dissociated to single cell suspension by 0.25% trypsin-EDTA (Invitrogen). DMEM media with 10% FBS (Sigma, v/v) was used to inactivate trypsin and cells were subjected to spin down at 300 g for 5 min. Cell pellet was washing once using D-PBS without calcium and magnesium and re-suspended in 200 μl of D-PBS in V-bottom plate. Cells were immediately transferred to LSR-II flowcytometer (BD) for data recording and analysis. The dead cells in the cell population were gated out and percentage of GFP (+) cells were calculated on live cells.

### ATAC-Seq {#S23}

Time-course ATAC-Seq on SFEBq organoids with duplicates at day 2, 4 and 6 were performed using Nextera DNA sample prep kit (Illumina) by following a protocol described elsewhere. 5×10^4^ cells were washed with cold D-PBS and resuspended in 50 μl of cold lysis buffer (CHP-118-C, Boston Bioproducts) and pelleted. Transposition reaction by Tn5 transposase was incubated in TD buffer at 37°C for 30 min. After purification with MinElute Kit (QIAGEN), transposed DNA fragments were amplified through PCR using bar-coded Nextera PCR primers. Extra number of PCR cycles were added by qPCR as described and amplified DNA products were subjected to another round of DNA purification using MinElute Kit. Libraries were sent to University of Michigan DNA Sequencing Core for quality control test based on Bioanalyzer and sequenced using HiSeq 2500 or 4000 with pair-end reads.

### RNA-Seq {#S24}

RNA isolation for RNA-seq was performed by combination of Trizol reagent (ThermoFisher Scientific) and RNeasy mini kit (QIAGEN). Day 2 \[WT, *Wdr5* KO groups (KO\#7 or KO\#18 without Dox for 48 h), *Wdr5* and *p53* KO groups (DKO\#7--11 or DKO\#18--17 without Dox for 48 h)\] or Day 6 EB RNA samples \[WT group, KO group (*Wdr5* KO \#3 without Dox), *Wdr5* KO \#3 with early (Dox added at 12 h after differentiation, T12h group) and late (Dox added at 48 h after differentiation, T48h group) WDR5 rescue\] were sent to University of Michigan DNA Sequencing Core for RNA quality analysis, library construction, and sequencing using Illumina HiSeq 4000 Libraries platform. Duplicate samples for each group were subjected to two round of independent library preparation and sequencing to avoid sample and batch effect of RNA-seq.

### ChIP-Seq {#S25}

Chromatin Immunoprecipitation (ChIP) assay were performed using a slightly modified version of ChIP Assay Kit (Millipore) based protocol as described previously. Day 6 EBs \[*Wdr5*^KO^ \#3 with early (Dox added at 12 h after differentiation, T12h group, total cell number 3×10^7^) and late (Dox added at 48 h after differentiation, T48h group, total cell number 4×10^7^) hWDR5 rescue were fixed with Disuccinimidyl glutarate crosslinker (COVAChem) at final concentration of 2 μM at room temperate for 30 min. Cells were further subjected to crosslink with 1% paraformaldehyde (Sigma) at room temperature at 10 min and the reaction was quenched using glycine at final concentration of 0.125M. The cells pellets were further sonicated to 300--500 bp in SDS lysis buffer by using a Biorupter 300 (Diagenode). 15 μg ChIP grade anti-HA antibody (ab9110, Abcam) was used for ChIP assay. The ChIP-DNA were sent to University of Michigan DNA Sequencing Core for quality control, library preparation, and sequencing using Illumina HiSeq 4000 Libraries platform.

### CUT&RUN {#S26}

Day 2 WT, *Wdr5*^KO^ and DKO EBs were harvested and trypsinized to single cell suspension. 2×10^6^ cells were prepared for Cut & Run experiment per antibody as previously described ([@R42]; [@R43]) and the following antibodies were used: WDR5 antibody (Bethyl), P53 antibody (NCL-L-P53-CM5P, Leica biosystems) and H3K4me3 antibody (Abcam). Protein A--micrococcal nuclease (pA-MN) fusion protein were generously provided by Dr. Steven Henikoff.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S27}
---------------------------------------

### Statistical Analysis {#S28}

All experiments were independently repeated with different *mWdr5* KO ESC clones at least for 2 to 4 times with similar results, and data from one representative experiment are presented unless otherwise stated. Two-tailed unpaired Student's t test was applied using GraphPad Prism (version 7.00) to determine whether the observed differences were statistically significant. Changes were considered statistically significant when p value less than 0.05.

### Bioinformatics Analysis {#S29}

#### Reads Mapping and Coverage {#S30}

All RNA-seq data were mapped to the mm10 genome for mouse, and hg38 genome for human, using Tophat2 (2.1.1) ([@R23]), which was shown to be accurate alignment of transcriptomes in the presence of insertions, deletions, and gene fusions. Then, duplicated reads for pair-end data were removed, but not single-end data by SAMtools (v1.5) ([@R27]). All ChIP-seq, ATAC-seq, and CUT&RUN sequencing data were mapped to the mm10 genome for mouse by using Bowtie2 (v2--2.2.4) with parameters "-q--phred33--very-sensitive -p 10" ([@R26]), which is ultrafast and memory-efficient tool for aligning sequencing reads to long reference sequences. Then, we removed any duplicated reads for both pair-end and single-end data using SAMtools (v1.5) ([@R27]). For all sequencing datasets, the bigwig files for visualization in Integrative Genomics Viewer (IGV) ([@R47]) were generated from BAM files by using "bamCoverage" from deepTools ([@R34]) with parameters "--ignoreDuplicates--normalizeUsingRPKM--skipNonCoveredRegions--binSize 50." The bigwig files for IP/input ratio were generated from BAM files by using deepTools2 (v2.5.0) ([@R35]) with command "bamCompare -b1 ChIP-bam -b2 Input-bam-ignoreDuplicates--minMappingQuality 30--normalizeUsing RPKM --binSize 20--operation ratio--scaleFactorsMethod None -p 20." Whereas, for ATAC-seq and CUT&RUN datasets, the bigwig files were generated from BAM files by using deepTools2 (v2.5.0) ([@R35]) with command "bamCoverage--outFileFormat bigwig--ignoreForNormalization chrM chrX chrY--skip-NAs-bam bowtie2.rmdup.bam-outFileName output.bigwig--normalizeUsing RPKM--minMappingQuality 30--binSize 20--smooth-Length 60--ignoreDuplicates--scaleFactor 1-numberOfProcessors 2."BAM files of mapping results were merged for the same sample using SAMtools and converted to BED format by using BEDTools ([@R33]). Peaks of regulatory regions were called for each sample by using MACS (v 1.4.2) ([@R59]) from bed files of ChIP-seq with parameters "-w -S -p 0.00001 -g mm." The input signal was used as the control to call peaks for the ChIP-seq dataset. The heatmap plot of signals centered on peaks was implicated by deepTools2. The heatmap plot of signals centered on peaks was implicated by deepTools2 subcommand plotHeatmap.

#### Peak Calling and Annotation {#S31}

BAM files of mapping results were merged for the same sample using SAMtools and converted to BED format by using BEDTools ([@R33]). Peaks of regulatory regions were called for each sample by using MACS (v 1.4.2) ([@R59]) from datasets of ChIP-seq with parameters "-w -S -p 0.00001." The input signal was used as the control to call peaks for the ChIP-seq dataset. The heatmap plot of signals centered on peaks and gene promoters was implicated by deepTools2 (v2.5.0) ([@R35]). Peak annotation was performed by using HOMER (v4.9.1) ([@R18]) with default parameters. Motif analysis on peak regions was performed with HOMER function findMotifsGenome.pl with parameters "-size 50 -mask."

DATA AND CODE AVAILABILITY {#S32}
--------------------------

The datasets generated during this study are available at Gene Expression Omnibus (GEO) repository with accession numbers GEO: GSE116153, GSE116154, GSE116155, and GSE140899.

The graphical abstract was created with [Biorender.com](http://Biorender.com).
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![WDR5 Induces *Rx*^+^ Neuroectoderm Differentiation via Its RbBP5 Interaction Surface\
(A and B) WDR5 regulates NE proliferation and differentiation in a dose-dependent manner. WT and *WDR5*^*Dox*^;*Wdr5*^*KO*^ ESCs were maintained in the Dox-containing ESC media. ESCs were resuspended in SFEBq differentiation (EB day 0) in different concentrations of Dox. Cell proliferation at EB day 4 (A) and *Rx*-GFP positive NE at EB day 5 (B) were determined.\
(C and D) Proliferation and NE differentiation in *WDR5*^*Dox*^; *Wdr5*^*KO*^ ESCs stably transfected with FLAG-tagged WT or different WDR5 mutants. Upon differentiation, Dox was removed (no Dox) or added back 12 h later (2.0 ug/ml, T12h). Cell proliferation was determined at EB day 4 and relative cell proliferation was normalized to the respective group with Dox as 1.0 (D). Percentage of Rx-GFP^+^ NE cells at EB day 5 was determined by flow cytometry (E).\
(E) Effects of WDR5-RbBP5 interaction mutants with or without Dox-induced WT WDR5 rescue on NE differentiation were determined by *Rax* mRNA qRT-PCR (EB day 6).\
(F) WT, but not WDR5-RbBP5 interaction mutant WDR5^Q289E^, retained capacity to induce *Rax*-GFP^+^ NE in *Wdr5*^*KO*^ EBs. Representative day 6 EBs were recorded under microscope using bright field or fluorescence channel. Scale bars: 50 μm.\
(G) Expression of Dox-inducible WDR5-RbBP5 interaction mutants was not able to induce Rx-GFP^+^ NE differentiation. *WDR5*^*Dex*^; *Wdr5*^*KO*^ ESCs (Δ26), maintained in dexamethasone (Dex) containing ES media, which enabled Dex-inducible WDR5 expression to maintain ESC self-renewal, were stably transfected with Dox-inducible forms of various HA-tagged WDR5 mutants. Upon differentiation, Dex was removed and Dox was added 12 h later (2.0 ug/ml, T12h). Percentage of Rx-GFP^+^ NE cells at EB day 7 was determined by flow cytometry.\
EV: empty vector backbone control. Data in (A)--(F), (G), (H), and (I) represent mean ± SD (n ≥ 3). \*\*p ≤ 0.01, \*\*\*p ≤ 0.001, and \*\*\*\*p ≤ 0.001.\
See also [Figures S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1549892-f0001){#F1}

![Prolonged *Wdr5* Inhibition Triggers Mesoderm Differentiation\
(A) A schematic outline of SFEBq differentiation in WT, and *WDR5*^*Dox*^;*Wdr5*^*KO*^ ESCs with early or extended void/rescue of Dox-inducible WDR5.\
(B) qRT-PCR mRNA analysis of pluripotent (Oct4), NE (*Rax/Rx*), and cardiac mesoderm (MES) markers (*cTnT*) during time-course SFEBq differentiation of WT, early (T12h^Rescue^) and extended void (T36h or 48h^Rescue^)/rescue of WDR5 in *Wdr5*^*KO*^ EBs.\
(C) Immunofluorescence staining on day 9 EB sections with neuroepithelial marker (N-cadherin), cardiac specific troponin T (CT3), and sarcomere myosin (MF20) in WT, early and extended void/rescue of WDR5 in *mWdr5*^*KO*^ EBs. DAPI was counterstained for nuclei. Scale bars: 100 μm.\
(D) Critical time points for WDR5-mediated *Rax/Rx*^*+*^ NE and cardiogenic MES fate choice in *Wdr5*^*KO*^ EBs were determined by *Rax* and *cTnT* mRNA expression (EB day 6).\
(E) Dose-dependent effects of WDR5 in *Wdr5*^*KO*^ EBs during WDR5 extended void on cardiogenic MES induction (*cTnT*and *αMHC*) and NE inhibition (*Pax6* and *Rax*). Samples were collected on EB day 6.\
(F) Cardiogenic MES induction by WDR5 extended void is not restricted to specific NE differentiation conditions. WT and *Wdr5*^KO^ EBs with WDR5 early or extended void were differentiated using SFEBq methods without Matrigel and Rx-inducing NE differentiation agent AGN. Induction of MES markers *T (Brachyury*) and *cTnT* was determined by qRT-PCR.\
(G) MES induction by prolonged deletion of *Wdr5* leads to hematopoietic differentiation. Upper panel: a schematic description of secondary hematopoietic cell colony-forming unit (CFU) assay using primary differentiating SFEBq organoids as test cells. Lower panel: the representative pictures of resultant secondary EBs and all CFU were presented at day 9 after secondary differentiation. Dox dose for primary differentiation: 2.0 ug/ml. Scale bars: 100 μm.\
(H) Effects of WDR5-RbBP5 interaction mutants with or without Dox-inducible WT WDR5 void on cardiogenic MES-specific transcription were determined by *cTnT* qRT-PCR (EB day 6).\
Data in (B), (D), (F), and (I) represent mean ± SD (n ≥ 3). \*\*\*\*p ≤ 0.001.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1549892-f0002){#F2}

![Early and Extended Void of WDR5 in *Wdr5*^*KO*^ EBs Activates Overlapping and Distinct Lineage-Determination Target Genes\
(A) Venn diagram of differentially expressed genes among groups for WT, *Wdr5*^*KO*^ with WDR5 early (T12h^Rescue^), or extended void (T48h^Rescue^) EBs (day 6).\
(B) GO and heatmap clustering analysis of differentially expressed genes in day 6 *Wdr5*^KO^ EBs with early (T12h^Rescue^) versus extended (T48h^Rescue^) void of WDR5.\
(C) Validation of RNA-seq data by qRT-PCR analysis of markers for trophectoderm (*Cdx2* and *Gata3*) and endoderm (*Gata4* and *Foxa2*) in WT or *Wdr5*^KO^ EBs with early or extended WDR5 void during time-course SFEBq differentiation.\
(D) Metaprofiles (upper panels) and heatmaps (lower panels) of HA-WDR5 ChIP-seq signals demonstrating overlapping and distinct WDR5 bound peaks in day 6 Wdr5^KO^ EBs with T12h^Rescue^ and T48h^Rescue^ settings using all peaks existing in the T12h^Rescue^ group (left panel) or T48h^Rescue^ group (right panel) as reference, respectively.\
(E) Heatmap demonstrating WDR5 direct target genes in day 6 *Wdr5*^KO^ EBs with T12h^Rescue^ and T48h^Rescue^ groups.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1549892-f0003){#F3}

![Prolonged Inhibition of *Wdr5* Leads to Dysregulated Target Gene Expression during mESC Lineage Specification\
(A) Volcano plots of down- and upregulated genes upon prolonged *Wdr5* deletion (EB day 2) determined by RNA-seq. ≥ 2-fold higher or lower differentially expressed genes are colored red and blue, respectively. KO-A and KO-B represents EBs differentiating from two independent *Wdr5*^KO^ ESC clones.\
(B) Heatmaps showing WDR5 and H3K4Me3 DNA binding peaks determined by CUT&RUN sequencing. WDR5-bound peaks in WT EBs that decreased due to *Wdr5* deletion in day 2 EBs (*Wdr5*^*KO*^;*p53*^*KO*^ DKO cells; see below) were called for H3K4Me3 peaks in WT and *Wdr5*^KO^ EBs at same time point (day 2).\
(C) Metaprofiles comparing mean RPKM of H3K4Me3 peaks centered on WDR5-bound loci (WT) in day 2 WT and *Wdr5*^KO^ EBs.\
(D) Heatmap displaying differential mRNA expression of WDR5 target genes upon prolonged *Wdr5* deletion (EB day 2).\
(E) Track views of ATAC-seq peak dynamics for a representative NE gene (*Rax*) and a cardiac MES gene (*cTnT*) in WT, *Wdr5*^KO^ EBs with T12h and T48h WDR5 void during time-course differentiation. The y axes were set as the same scale by group autoscale in Integrative Genomics Viewer.\
(F) Metaprofiles showing correlation of ATAC-seq peaks with H3K4Me3 CUT&RUN sequencing peaks for day 2 WT and *Wdr5*^KO^ EBs. Genome-wide H3K4Me3 peaks lost by *Wdr5* prolonged deletion were furtherly called for ATAC-seq change.\
(G) GO analysis of closing and opening peaks by ATAC-seq analysis in *Wdr5*^KO^ EBs at day 2.\
See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1549892-f0004){#F4}

![*p53* Deletion Represses Cardiogenic MES Induction Linked to Extended Wdr5 Inhibition and Partially Rescues NE Differentiation\
(A) Cell proliferation in day 4 *Wdr5*^KO^ and DKO EBs with or without WDR5 void.\
(B) NE differentiation in WT, *Wdr5*^KO^, and DKO EBs without WDR5 void (no Dox), or with early (Dox, T12h) or extended (Dox, T44h) WDR5 void, was determined by flow cytometry for Rx(+)-GFP cells at day 6.\
(C) *Rx*^*+*^ NE differentiation by early WDR5 void in DKO EBs is WDR5 dose-dependent. Samples were analyzed at EB day 6.\
(D) Representative images (EB day 7) of *Rx*^*+*^ NE and cardiogenic MES fate choice in WT, *Wdr5*^KO^, and DKO EBs with early or extended WDR5 void. Scale bars: 50 μm.\
(E) qRT-PCR analysis of NE (*Rax/Rx* and *Pax6*) and MES (*cTnT*) specific markers in WT, *Wdr5*^KO^, and DKO EBs with early or extended WDR5 void. Samples were collected on EB day 10.\
(F) Metaprofiles and heatmaps of ATAC-seq closing and opening peaks in WT, *Wdr5*^KO^, and DKO EBs with early or extended WDR5 void. Samples were analyzed at EB day 6.\
Data in (A)--(C) and (E) represent mean ± SD (n ≥ 3). \*\*\*\*p ≤ 0.001.\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1549892-f0005){#F5}

![WDR5 Regulates p53-Dependent Gene Regulation during ESC Specification\
(A) Metaprofiles for ATAC-seq chromatin accessibility in closing (left panel) and opening (right panel) peaks in day 2 *Wdr5*^KO^ EBs partially rescued by *p53* deletion.\
(B) Boxplots for downregulated (left panel) and upregulated (right panel) genes from RNA-seq show that transcriptional defects in day 2 *Wdr5*^*KO*^ EBs (versus WT) are partially rescued by *p53* deletion. For downregulated genes, WT versus KO-A or KO-B: p = 2.2e--16. KO-A versus KO-A derived DKO-A: p = 0.009. KO-B versus KO-B derived DKO-B: p = 2.2e--16. For upregulated genes, WT versus KO-A or KO-B: p = 2.2e--16. KO-A versus KO-A derived DKO-A: p = 2.2e--16. KO-B versus KO-B derived DKO-B: p = 2.2e--16.\
(C) qRT-PCR validation of partially rescued genes *E2f3 and Cdkn1a* in day 2 or day 3 *Wdr5*^KO^ EBs by *p53* deletion. Data represent mean ± SD (n ≥ 3). \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001.\
(D) Metaprofiles displaying H3K4Me3 peaks centered at WDR5-bound loci (WT) were reduced in day 2 *Wdr5*^KO^ EBs, but were partially reversed (rescued) by *p53* deletion (DKO EBs).](nihms-1549892-f0006){#F6}

![WDR5 Controls Posttranscriptional Regulation of p53 and Directly Interacts with p53 during ESC Lineage Specification\
(A) qRT-PCR analysis of *p53* mRNA in WT and *Wdr5*^*KO*^ EBs at days 2 and 3.\
(B) Track views of WDR5-bound peaks at TSS regions of *Rpl5* and *Rpl29* gene in day 2 WT and DKO EBs determined by CUT&RUN sequencing. The y axes were set as the same scale by group autoscale in Integrative Genomics Viewer.\
(C) qRT-PCR validation of mRNA expression of ribosomal protein (RP) genes in day 2 WT and *Wdr5*^KO^ EBs.\
(D) Western blot showing p53 levels in day 2 WT and *Wdr5*^KO^ EBs treated with cycloheximide (CHX, 50 μg/ml) for different time points. Right panel: quantification of p53 levels relative to loading control β-actin. Relative p53 level at time 0 of each group was set as 1.0.\
(E) Physical interaction of endogenous WDR5 and p53 determined by immunoprecipitation (IP). EB day 2 WT and DKO cell lysates were precipitated with p53 antibody. IP elutions were probed with WDR5 and p53 antibodies, respectively. β-actin served as input loading control.\
(F) Heatmaps showing p53-bound peaks determined by CUT&RUN sequencing on day 2 WT and DKO EBs.\
(G) Track views of WDR5 and p53 co-bound peaks at the TSS region of *Rap2b* gene in day 2 WT and DKO EBs, as determined by CUT&RUN. The y axes were set as the same scale by group autoscale in Integrative Genomics Viewer.\
(H) qRT-PCR showing upregulation of *Rap2b* mRNA in day 2 *Wdr5*^KO^ EBs and partial rescue (downregulation) of *Rap2b* transcription due to *p53* deletion. Data in (A), (C), and (H) represent mean ± SD (n ≥ 3). \*\*p ≤ 0.05, \*\*p ≤ 0.01, \*\*\*p ≤ 0.001, and \*\*\*\*p ≤ 0.001.\
See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms-1549892-f0007){#F7}

  REAGENT or RESOURCE                                                              SOURCE                                          IDENTIFIER
  -------------------------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------------
  Antibodies                                                                                                                       
  Anti-WDR5                                                                        Bethyl                                          Cat\# A302-429A, RRID:AB_1944302
  Anti-WDR5                                                                        Bethyl                                          Cat\# A302-430A, RRID:AB_1944300
  Anti-WDR5                                                                        R & D Systems                                   Cat\# AF5810, RRID:AB_2215565
  Anti-HA                                                                          Abcam                                           Cat\# ab9110, RRID:AB_307019
  anti-FLAG                                                                        Sigma                                           Cat\# F3165, RRID:AB_259529
  anti-H3                                                                          Abcam                                           Cat\# ab1791, RRID:AB_302613
  anti-H3K4Me1                                                                     Millipore                                       Cat\# 07-436, RRID:AB_310614
  anti-H3K4Me2                                                                     Millipore                                       Cat\# 07-030, RRID:AB_11213050
  anti-H3K4Me3                                                                     Abcam                                           Cat\# ab8580, RRID:AB_306649
  anti-p53                                                                         Cell Signaling Technology                       Cat\# 32532, RRID:AB_2757821
  anti-p53                                                                         Leica Biosystems                                Cat\# NCL-L-P53-CM5P
  anti-α/β-Tubulin                                                                 Cell Signaling Technology                       Cat\# 2148, RRID:AB_2288042
  Anti-β-Actin                                                                     Abcam                                           Cat\# ab49900, RRID:AB_867494
  anti-p53 (acetyl K305)                                                           Abcam                                           Cat\# ab109396, RRID:AB_10861725
  anti-p53 (phospho S392)                                                          Abcam                                           Cat\# ab33889, RRID:AB_776988
  anti-Phospho-p53 (Ser15)                                                         Cell Signaling Technology                       Cat\# 12571, RRID:AB_2714036
  anti-N-cadherin                                                                  BD Biosciences                                  Cat\# 610920, RRID:AB_2077527
  anti-myosin, sarcomere (MHC) antibody                                            DSHB                                            Cat\# MF 20, RRID:AB_2147781
  anti-troponin T (cardiac/slow) antibody                                          DSHB                                            Cat\# ct3, RRID:AB_528495
  Anti-p53, acetyl (Lys379)                                                        Cell Signaling Technology                       Cat\# 2570, RRID:AB_823591
  Anti-mouse IgG, HRP-linked Antibody                                              Cell Signaling Technology                       Cat\# 7076, RRID:AB_330924
  Anti-rabbit IgG, HRP-linked Antibody                                             Cell Signaling Technology                       Cat\# 7074, RRID:AB_2099233
  Donkey Anti-Goat IgG HRP Affinity Purified PAb antibody                          R & D Systems                                   Cat\# HAF109, RRID:AB_357236
  Peroxidase IgG Fraction Monoclonal Mouse Anti-Rabbit IgG, light chain specific   Jackson ImmunoResearch Labs                     Cat\# 211-032-171, RRID:AB_2339149
  Chemicals, Peptides, and Recombinant Proteins                                                                                    
  AGN 193109 Sodium Salt                                                           Santa Cruz Biotechnology                        Cat\# sc-210768
  Dexamethasone                                                                    Sigma                                           Cat\# D4902
  Cycloheximide solution                                                           Millipore                                       Cat\# C4859
  KnockOut Serum Replacement                                                       GIBCO                                           Cat\# 10828028
  Matrigel® Growth Factor Reduced (GFR) Basement Membrane Matrix                   CORNING                                         Cat\# 354230
  Glasgow's MEM (GMEM)                                                             GIBCO                                           Cat\# 11710-035
  Sodium Pyruvate (100 mM)                                                         GIBCO                                           Cat\# 11360070
  MEM Non-Essential Amino Acids Solution (100X)                                    GIBCO                                           Cat\# 11140050
  TRIzol                                                                           Thermo Fischer                                  Cat\# 15596026
  iQ SYBR® Green Supermix                                                          Bio-Rad                                         Cat\# 1708880
  TaqMan Gene Expression Master Mix                                                Thermo Fischer                                  Cat\# 4369016
  RIPA Lysis and Extraction Buffer                                                 Thermo Fischer                                  Cat\# 89900
  Cold lysis buffer                                                                Boston Bioproducts                              Cat\# CHP-118-C
  Disuccinimidyl glutarate crosslinker                                             COVAChem                                        Cat\# 13301
  Dynabeads Protein G for Immunoprecipitation                                      Thermo Fisher                                   Cat\# 10003D
  VECTASHIELD® Hardset Antifade Mounting Medium with DAPI                          Vector Laboratories                             Cat\# H-1500
  Protein A-micrococcal nuclease                                                   Dr. Steve Henikoff                              N/A
  Critical Commercial Assays                                                                                                       
  Nunclon Sphera Microplates                                                       Thermo Fisher                                   Cat\# 174925
  In-Fusion® HD Cloning Plus                                                       Takara                                          Cat\# 638909
  Mouse ES cell nucleofector® kit                                                  Lonza                                           Cat\# VPH-1001
  ZymoPURE II Plasmid Midiprep Kit                                                 Zymo                                            Cat\# D4200
  RNeasy Mini Kit                                                                  QIAGEN                                          Cat\# 74104
  High-capacity RNA-to-cDNA kit                                                    Thermo Fisher                                   Cat\# 4387406
  Histone extraction kit                                                           Abcam                                           Cat\# ab113476
  Pierce BCA Protein Assay Kit                                                     Thermo Fisher                                   Cat\# 23225
  Invitrogen Molecular Probes TSA Kit 24                                           Thermo Fisher                                   Cat\# T20934
  Mouse on Mouse (M.O.M.®) Elite® Peroxidase Kit                                   Vector Laboratories                             Cat\# PK-2200
  Nextera DNA sample prep kit                                                      Illumina                                        Cat\# 15028212
  MinElute PCR Purification Kit                                                    QIAGEN                                          Cat\# 28004
  Chromatin Immunoprecipitation (ChIP) Assay Kit                                   Millipore                                       Cat\# 17-295
  Deposited Data                                                                                                                   
  ATAC-seq Data                                                                    This Study                                      GSE116153
  RNA-seq Data                                                                     This Study                                      GSE116155
  ChIP-seq Data                                                                    This Study                                      GSE116154
  CUT&RUN Data                                                                     This Study                                      GSE140899
  Experimental Models: Cell Lines                                                                                                  
  Rx-GFP K/I EB5 (sex: Male \[XY\])                                                RIKEN                                           Cat\# AES0145
  Oligonucleotides                                                                                                                 
  Wdr5 guide RNA:TGTGAAGTTCAGCCCCAATG                                              This Study                                      N/A
  p53 guide RNA \#1:AAAATGTCTCCTGGCTCAGA                                           This Study                                      N/A
  p53 guide RNA \#2:ATAAGCCTGAAAATGTCTCC                                           This Study                                      N/A
  Recombinant DNA                                                                                                                  
  pPBCAG-rtTM2-IN                                                                  Dr. Hitoshi Niwa (Kumamoto University, Japan)   N/A
  Transposase pBase                                                                Dr. Hitoshi Niwa (Kumamoto University, Japan)   N/A
  pPBCMV1cHApA                                                                     This Study                                      N/A
  pPBCMV1-WT-WDR5-HA                                                               This Study                                      N/A
  pPBCMV1-L240K-WDR5-HA                                                            This Study                                      N/A
  pPBCMV1-V268E-WDR5-HA                                                            This Study                                      N/A
  pPBCMV1-Q289E-WDR5-HA                                                            This Study                                      N/A
  pPBTREG/Tet3G-FLAG-WT-WDR5                                                       This Study                                      N/A
  pPBTREG/Tet3G-FLAG-N225A-WDR5                                                    This Study                                      N/A
  pPBTREG/Tet3G-FLAG-L240K-WDR5                                                    This Study                                      N/A
  pPBTREG/Tet3G-FLAG-V268E-WDR5                                                    This Study                                      N/A
  pPBTREG/Tet3G-FLAG-Q289E-WDR5                                                    This Study                                      N/A
  PiggyBac-FLAG-WT-WDR5-GRBD                                                       This Study                                      N/A
  PiggyBac-FLAG-WT-WDR5                                                            This Study                                      N/A
  PiggyBac-FLAG-F133Y-WDR5                                                         This Study                                      N/A
  PiggyBac-FLAG-I305V-WDR5                                                         This Study                                      N/A
  PiggyBac-FLAG-N225A-WDR5                                                         This Study                                      N/A
  PiggyBac-FLAG-L240K-WDR5                                                         This Study                                      N/A
  PiggyBac-FLAG-V268E-WDR5                                                         This Study                                      N/A
  PiggyBac-FLAG-Q289E-WDR5                                                         This Study                                      N/A
  Software and Algorithms                                                                                                          
  Image lab Version 5.2.1                                                          Bio-Rad                                         <https://www.bio-rad.com/en-us/product/image-lab-software?ID=KRE6P5E8Z>
  GraphPad Prism Version 7.00                                                      GraphPad Software                               <https://www.graphpad.com/scientific-software/prism/>
  SAMtools Version 1.5                                                             [@R27]                                          <http://www.htslib.org/>
  Bowtie2 Version 2--2.2.4                                                         [@R26]                                          <http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>
  deepTools Version 2.5.0                                                          [@R34]                                          <https://deeptools.readthedocs.io/en/develop/>
  BEDTools                                                                         Quinlan and Hall, 2008; PMID: 20110278          <https://bedtools.readthedocs.io/en/latest/>
  MACS Version 1.4.2                                                               [@R59]                                          <https://github.com/taoliu/MACS/>
  HOMER Version 4.9.1                                                              [@R18]                                          <http://homer.ucsd.edu/homer/>

###### Highlights

-   WDR5-RbBP5 interaction surface controls ESC-to-neuroectoderm organoid differentiation

-   *Wdr5* inhibition stabilizes p53 and activates p53 signaling

-   Transient *Wdr5* inhibition stimulates ESC differentiation toward mesoderm fates via p53
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